Factors contributing to the high prevalence of multidrug-resistant tuberculosis: A study from China

Thorax

Volumn 67, Issue 7, 2012, Pages 632-638

  Liang, Libo ^a   Wu, Qunhong ^a   Gao, Lijun ^a   Hao, Yanhua ^a   Liu, Chaojie ^b   Xie, Yanguang ^c   Sun, Hong ^a   Yan, Xinglu ^c   Li, Fabin ^c   Li, Honghai ^c   Fang, Hongxia ^c,d   Ning, Ning ^a   Cui, Yu ^a   Han, Liyuan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b LA TROBE UNIVERSITY   (Australia)

^c Heilongjiang Provincial Center for STD Prevention and Control   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHINA; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; INAPPROPRIATE PRESCRIBING; INTERVIEW; KNOWLEDGE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SPUTUM CULTURE; THERAPY DELAY; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT;

EID: 84862766396     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200018     Document Type: Article

References (35)

1. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
2. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005;73-74:17-24.
3. World Health Organization. Multidrug and Extensively Drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Switzerland, Geneva: World Health Organization, 2010.
4. World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing. Switzerland, Geneva: World Health Organization, 2009.
5. World Health Organization. A Ministerial Meeting of High M/XDR-TB Burden Countries. Geneva, Switzerland: World Health Organisation, 2009.
6. Wang L, Liu J, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. Lancet 2007;369:691-6.
7. Yang XY, Li YP, Mei YW, et al. Time and spatial distribution of multidrug-resistant tuberculosis among Chinese people, 1981-2006: a systematic review. Int J Infect Dis 2010;14:e828-37.
8. Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis 2009;13:68-73.
9. Moniruzzaman A, Elwood RK, Schulzer M, et al. A population-based study of risk factors for drug-resistant TB in British Columbia. Int J Tuberc lung Dis 2006;10:631-8.
10. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez JL, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 2009;28:325-30.
11. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006;61:158-63.
12. He GX, Zhao YL, Jiang GL, et al. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis 2008;8:166.
13. Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors. Int J Tuberc Lung Dis 2009;13:253-9.
14. Chen J, Li NX, Wan KL, et al. Analysis on risk factors of drug resistance for tuberculosis in Sichuan and Anhui province (In Chinese). J Sichuan Univ (Med Sci Edi) 2007;38:135-7.
15. Xie YG, Li FB, Yan XL. WHO TB drug resistance survey in Heilongjiang province. Chin J Antituberculosis Association 2008;30:395-8.
16. World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis. Geneva, Switzerland: World Health Organization, 1997.
17. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. 3rd edn. Geneva: World Health Organization, 2003.
18. Merlo J. Multilevel analytical approaches in social epidemiology: measures of health variation compared with traditional measures of association. J Epidemiol Community Health 2003;57:550-2.
19. Hox JJ. Multilevel Analysis, Techniques and Application. Mahwah, NJ: Lawrence Erlbaum Associates, 2002.
20. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of mycobacterium tuberculosis. Lancet Infect Dis 2003;3:13-21.
21. Ano H, Matsumoto T, Suetake T, et al. Relationship between the isoniazid-resistant mutation katGS315T and the prevalence of MDR-/XDR-TB in Osaka, Japan. Int J Tuberc Lung Dis 2008;12:1300-5.
22. Marquina-Castillo B, Garcia-Garcia L, Ponce-de-León A, et al. Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model. Immunology 2009;128:123-33.
23. Shen G, Xue Z, Shen X, et al. The study recurrent tuberculosis and exogenous reinfection, Shanghai, China. Emerg Infect Dis 2006;12:1776-8.
24. Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008;46:42-9.
25. Seung KJ. Does my patient have multidrug-resistant tuberculosis? Clin Infect Dis 2010;51:379-80.
26. Laniado-Laborin R. Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered. Expert Rev Respir Med 2010;4:143-6.
27. Nic Fhogartaigh CJ, Vargas-Prada S, Huancare V, et al. Physician-initiated courtesy MODS testing for TB and MDR-TB diagnosis and patient management. Int J Tuberc Lung Dis 2008;12:555-60.
28. Chen Q, Zheng J, Wu N. Analysis on the correlated factors of delay in tuberculosis diagnosis and treatment in Fujian province. Chin J Antituberculosis Association 2005;27:374-9.
29. Wang W, Jiang Q, Abdullah AS, et al. Barriers in accessing to tuberculosis care among non-residents in Shanghai: a descriptive study of delays in diagnosis. Eur J Public Health 2007;17:419-23.
30. Xia Y, Zhan S. Systematic review of anti-tuberculosis drug induced adverse reactions in China (In Chinese). Chin J Tuberc Respir Dis 2007;30:419-23.
31. Yan F, Jiang Q. Current Situation and Strategy for Tuberculosis Control in China, Social Assessment Study in Four Provinces. Fudan University, Shanghai, doctor dissertation, 2007.
32. Meng Q, Li R, Cheng G, et al. Provision and financial burden of TB services in a financially decentralized system: a case study from Shandong, China. Int J Health Plann Manage 2004;19(Suppl 1):S45-62.
33. World Health Organization. Tuberculosis Control in the Western Pacific Region: 2009 Report. Geneva: World Health Organization, 2009.
34. Tang S, Squire SB. What lessons can be drawn from tuberculosis (TB) control in China in the 1990s? An analysis from a health system perspective. Health Policy 2005;72:93-104.
35. Zhang J, Luo J, Wang L, et al. The analysis of HIV/AIDS epidemic in Heilongjiang province from 1993 to 2004. Chin J AIDS STD 2005;11:264-6.